110 related articles for article (PubMed ID: 31611441)
1. Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma.
Zhou B; Li L; Shi D; Jiang T; Xue G; Xiong J
Indian J Pathol Microbiol; 2019; 62(4):566-571. PubMed ID: 31611441
[TBL] [Abstract][Full Text] [Related]
2. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
[TBL] [Abstract][Full Text] [Related]
3. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
6. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
10. [To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].
Sun PL; Liu JN; Cao LQ; Yao M; Gao HW
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):303-308. PubMed ID: 28468034
[No Abstract] [Full Text] [Related]
11. Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma.
Aras G; Kanmaz ZD; Tuncay E; Çetinkaya E; Yentürk E; Kocatürk C; Öz B; Çermik TF; Purisa S
Tumori; 2019 Dec; 105(6):501-508. PubMed ID: 31910789
[TBL] [Abstract][Full Text] [Related]
12. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
13. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
14. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.
Lee J; Lee DH; Park JE; Lee YH; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Korean J Intern Med; 2024 Mar; 39(2):318-326. PubMed ID: 38351680
[TBL] [Abstract][Full Text] [Related]
17. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
19. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
